English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

© 2010 The Authors. doi: 10.2340/00015555-0952 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 Atopic dermatitis (AD) is a common, multifactorial inflammatory skin disease with a profound negative impact on quality of life of patients and their families. First-line treatments include topical steroids and topical calcineurin inhibitors (1). Treatment with ultraviolet (UV) radiation and oral antibiotics may be needed. Second-line therapy includes immunosuppressive drugs, such as azathioprine, cyclosporine, systemic prednisolone, or methotrexate (2). In some patients the disease takes a severe chronic course recalcitrant to these traditional firstand secondline therapies. In such cases, unconventional and less standardized third-line treatment regimes may be sought in order to ameliorate the disease effectively. Extracorporeal photopheresis (ECP) is a leukapheresisbased therapy that uses 8-methoxypsoralen (8-MOP) and UVA irradiation (3). A series of small open-labelled studies have shown the effect of ECP in patients with severe, recalcitrant AD (4–7). The treatment seems to be safe, as no adverse events have been reported. Most of the studies are, however, based on relatively shortterm application of ECP.

A Retrospective Study of Six Cases of Severe Recalcitrant Atopic Dermatitis Treated with Long-term Extracorporeal Photopheresis